BACKGROUND: The Intergroup 0116 study demonstrated that concurrent chemoradiation improved overall survival (OS) in resected @entity356 . However, there are few reports focusing on late @entity137 and factors governing prognosis. This study aimed to determine these two important aspects for employing this regimen. METHODS: @entity1 with resected @entity356 stage @entity66 , treated between July 1998 and December 2007, were analyzed. The majority of the @entity1 were treated using 5 cycles of @entity1487 ( @entity1487 )/ @entity4181 chemotherapy with 45 Gy/25 fractions radiotherapy concurrent with cycles 2 and 3, as per the Intergroup 0116 study. RESULTS: We treated 120 @entity1 (107 standard protocol, 13 with concurrent @entity1487 alone), and 14% had a close or positive margin. Median age was 59 years (35-79 years). Acute @entity137 >= grade 3 was seen in 66% of all @entity1 (hematological 61%, @entity3136 3%, @entity294 6%, @entity391 2%). Median follow-up was 33 months (range 6-125 months). Five-year OS and relapse-free survival were 51 and 54%, respectively. On multivariate analysis, surgical margin status, stage of the disease, and radiotherapy with computed tomography (CT) planning were important prognostic factors. @entity417 and @entity3621 were the two most frequently occurring late complications, though they were usually mild and asymptomatic. Clinically significant @entity8 was uncommon. Other rare complications included @entity1321 , @entity8884 , @entity101 , and secondary malignancy. CONCLUSIONS: Postoperative chemoradiation is safe and late @entity137 is usually mild in extent. Results were comparable to the Intergroup 0116 study. R0 resection is of utmost importance and radiotherapy should best be delivered by conformal techniques.

Adjuvant chemoradiation for resected XXXX : a 10-year experience.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal impairment'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis'] @entity66 :: ('MESH:D004194', 'Disease') :: ['IB to IV (M0) disease'] @entity417 :: ('MESH:D000740', 'Disease') :: ['Anemia'] @entity8884 :: ('MESH:D008286', 'Disease') :: ['malabsorption'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity3621 :: ('MESH:D005756', 'Disease') :: ['gastritis'] @entity1321 :: ('MESH:D007415', 'Disease') :: ['intestinal obstruction'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5FU', '5-fluorouracil']
@entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']
